Bolt Biotherapeutics
NEWS
Innate immune-oncology company Bolt expects to raise $230 million, and cancer cell therapy player Vor Biopharma expects to raise $176.9 million, in upsized initial public offerings (IPOs) starting today, following yesterday’s $587.5 million IPO for Sana Biotechnology and other financing news this week.
Clinical-stage biotechnology company Bolt Biotherapeutics announced today that it has completed a $93.5 million Series C round of financing, led by Sofinnova Investments.
Pharma, biotech and life sciences companies bolster their executive teams and boards with these Movers & Shakers.
Biopharma companies strengthen their leadership teams and boards with this week’s Movers & Shakers.
JOBS
IN THE PRESS